Strategy

News

Novartis raises mid-term sales outlook on pipeline promise

Novartis has raised its guidance for sales growth out to 2029 on the strength of its pipeline and the potential of late-stage R&D assets

News

23andMe stock sell-off adds to its woes

Shares in genetic testing company 23andMe continue to slide after prominent investors announce plans to sell their stakes

News

23andMe ends drug development and slashes staff

23andMe's big push into drug development, announced with great fanfare almost a decade ago, has ended with a whimper and sweeping job losses.

News

Pfizer rebuffs Starboard criticism as it raises forecasts

Pfizer chief executive Albert Bourla hit back at Starboard Value in its third-quarter results call, criticising the activist investor for complaining about the company's direction without c

Patients

Partner Content

How walking in a patient's shoes adds value to your patient ...

Imagine the difference it would make if everyone in your organisation had firsthand experience of living with one of the conditions you help treat. What insights would you gain?

News

Starboard spells out its concerns with Pfizer's direction

Activist investor Starboard Value has launched a broadside against Pfizer's leadership under chief executive Albert Bourla, claiming at least $20 billion in value – and possibly as much as

Novartis raises mid-term sales outlook on pipeline promise

23andMe stock sell-off adds to its woes

23andMe ends drug development and slashes staff

Pfizer rebuffs Starboard criticism as it raises forecasts

How walking in a patient's shoes adds value to your patient ...

Starboard spells out its concerns with Pfizer's direction

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Strategy

Editor's Picks